SYDNEY, July 6, 2020 /PRNewswire/ -- CardieX Limited (ASX: CDX, CardieX, the Company) 100% subsidiary ATCOR has submitted a US patent application in regards to its recently announced wearable sensor technology (ASX: 24/04/2020).
The new US Provisional Patent Application 63/031,645 describes a system and method of measuring medically reliable heart & arterial health indicators from a plethysmogram ("PPG") light sensor on a wearable device such as a smartwatch or mobile phone when a user places his/her finger on the sensor. The determination of a pulse rate with significant heart and arterial health indicators by way of the patent could previously only be obtained invasively or via a medical device in a clinical setting.
PPG sensors are the most widely used sensors on wearable devices and are incorporated into a broad range of wearable devices produced by the world's leading technology companies such as Apple, Samsung, Garmin, Mobvoi, Fitbit, and others.
The global wearable medical device market size was valued at USD13.0 billion in 2019 and is expected to witness a CAGR of 27.9% over the next 7 years with remote patient monitoring of cardiovascular disease and patient risk via non-invasive wearable devices expected to play a major role in the management of global health populations.
CardieX CEO Craig Cooper commented:
"We are already the world leader in measuring arterial stiffness and central blood pressure through our FDA-cleared SphygmoCor® technology that analyzes central arterial waveforms. In fact, we are the only FDA-cleared device that provides clinicians a full range of arterial features for managing hypertension in adults with SphygmoCor® XCEL. Our plan is to take that leadership position and replicate the same FDA-cleared technology from our medical devices into wearables in order to provide advanced medical diagnostics and health information to consumers – and to build a patent portfolio around our engineering successes to drive increased value for shareholders."
On the commercial application of the patent going forward Cooper also commented:
"The first application of the patent will most likely be with Google-backed Mobvoi in China as part of our development agreement with that company—but we also intend to license the technology to other wearable and smartwatch companies and to include it in our own medical and consumer wearable devices. Further updates and details of our device strategy will be announced shortly."
About CardieXCardieX is a global health technology company that develops digital and device-based solutions for large-scale population health disorders. The Company's SphygmoCor® XCEL device (developed & marketed by 100% subsidiary ATCOR) is the world leader in measuring "central blood pressure" which is considered essential for the management of hypertension and related cardiovascular disorders.
ATCOR's SphygmoCor® technology enables researchers and clinicians to non-invasively measure central blood pressure which provides clinicians with better prognostic and diagnostic information to target interventions—effects which cannot be detected with standard brachial blood pressure measurement alone.
More than 4,000 SphygmoCor systems are currently in use worldwide at major medical institutions, research institutions, and in various clinical trials with leading pharmaceutical companies. ATCOR's technology is also featured in over 1,400 peer-reviewed publications in leading medical journals.
www.cardiex.comwww.atcormedical.com
Advertisement
The new US Provisional Patent Application 63/031,645 describes a system and method of measuring medically reliable heart & arterial health indicators from a plethysmogram ("PPG") light sensor on a wearable device such as a smartwatch or mobile phone when a user places his/her finger on the sensor. The determination of a pulse rate with significant heart and arterial health indicators by way of the patent could previously only be obtained invasively or via a medical device in a clinical setting.
Advertisement
PPG sensors are the most widely used sensors on wearable devices and are incorporated into a broad range of wearable devices produced by the world's leading technology companies such as Apple, Samsung, Garmin, Mobvoi, Fitbit, and others.
The global wearable medical device market size was valued at USD13.0 billion in 2019 and is expected to witness a CAGR of 27.9% over the next 7 years with remote patient monitoring of cardiovascular disease and patient risk via non-invasive wearable devices expected to play a major role in the management of global health populations.
CardieX CEO Craig Cooper commented:
"We are already the world leader in measuring arterial stiffness and central blood pressure through our FDA-cleared SphygmoCor® technology that analyzes central arterial waveforms. In fact, we are the only FDA-cleared device that provides clinicians a full range of arterial features for managing hypertension in adults with SphygmoCor® XCEL. Our plan is to take that leadership position and replicate the same FDA-cleared technology from our medical devices into wearables in order to provide advanced medical diagnostics and health information to consumers – and to build a patent portfolio around our engineering successes to drive increased value for shareholders."
On the commercial application of the patent going forward Cooper also commented:
"The first application of the patent will most likely be with Google-backed Mobvoi in China as part of our development agreement with that company—but we also intend to license the technology to other wearable and smartwatch companies and to include it in our own medical and consumer wearable devices. Further updates and details of our device strategy will be announced shortly."
About CardieXCardieX is a global health technology company that develops digital and device-based solutions for large-scale population health disorders. The Company's SphygmoCor® XCEL device (developed & marketed by 100% subsidiary ATCOR) is the world leader in measuring "central blood pressure" which is considered essential for the management of hypertension and related cardiovascular disorders.
ATCOR's SphygmoCor® technology enables researchers and clinicians to non-invasively measure central blood pressure which provides clinicians with better prognostic and diagnostic information to target interventions—effects which cannot be detected with standard brachial blood pressure measurement alone.
More than 4,000 SphygmoCor systems are currently in use worldwide at major medical institutions, research institutions, and in various clinical trials with leading pharmaceutical companies. ATCOR's technology is also featured in over 1,400 peer-reviewed publications in leading medical journals.
www.cardiex.comwww.atcormedical.com
View original content:http://www.prnewswire.com/news-releases/cardiex-subsidiary-atcor-submits-new-us-patent-for-medical-wearable-sensor-technology-301087987.html
SOURCE CardieX Limited
